I think you are misunderstanding the resignations. They resigned because they didn't agree with the approval. > The latest exit comes from Dr. Aaron Kesselheim

I think you are misunderstanding the resignations. They resigned because they didn't agree with the approval. > The latest exit comes from Dr. Aaron Kesselheim, a professor at Harvard Medical School who is also director of the Program On Regulation, Therapeutics, And Law at Brigham and Women's Hospital. He said the FDA is greenlighting Aduhelm despite not having enough proof that the drug will help Alzheimer's patients.